Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: k-Strophanthin-beta
RN: 560-53-2
UNII: K935S3T1OE
InChIKey: FHIREUBIEIPPMC-SADZTDHOSA-N

Note

  • Contains beta-glucose, cymarose & strophanthidin.

Molecular Formula

  • C36-H54-O14

Molecular Weight

  • 710.8086
 
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • k-Strophanthin-beta

Synonyms

  • 5-18-05-00132 (Beilstein Handbook Reference)
  • beta-k-Strophanthin
  • beta-Strophanthobioside, strophanthidin-3
  • BRN 0076510
  • EINECS 209-210-9
  • NSC 4320
  • Strophanthidin-glucocymarosid
  • Strophanthidin-glucocymarosid [German]
  • Strophanthin
  • Strophanthin K
  • UNII-K935S3T1OE

Systematic Names

  • (3beta,5beta)-3-((2,6-Dideoxy-4-O-beta-D -glucopyranosyl-3-O-methyl-beta-D -ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxocard-20(22)-enolide
  • 5-beta-Card-20(22)-enolide, 3-beta-((2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-
  • k-Strophanthin-beta; Card-20(22)-enolide, 3-((2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-, (3beta,5beta)- (9CI)

Registry Numbers

CAS Registry Number

  • 560-53-2

FDA UNII

  • K935S3T1OE

System Generated Number

  • 0000560532

Structure Descriptors

InChI

1S/C36H54O14/c1-18-31(50-32-30(42)29(41)28(40)25(15-37)49-32)24(45-3)13-27(47-18)48-20-4-9-34(17-38)22-5-8-33(2)21(19-12-26(39)46-16-19)7-11-36(33,44)23(22)6-10-35(34,43)14-20/h12,17-18,20-25,27-32,37,40-44H,4-11,13-16H2,1-3H3/t18-,20+,21-,22+,23-,24+,25-,27+,28-,29+,30-,31-,32+,33-,34+,35+,36+/m1/s1

InChIKey

FHIREUBIEIPPMC-SADZTDHOSA-N

Smiles

C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LDLo intravenous 140ug/kg (0.14mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 1854, 1972.
cat LDLo oral 6mg/kg (6mg/kg)   Farmacognosia. Vol. 13, Pg. 375, 1953.
cat LDLo unreported 128ug/kg (0.128mg/kg)   "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963Vol. -, Pg. 124, 1963.
mouse LD50 intraperitoneal 1071ug/kg (1.071mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse LD50 subcutaneous 213ug/kg (0.213mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,